Frontiers in Oncology · 12 Nov 2026
Young-onset lung cancer: a clinician’s guide from diagnosis to survivorship
Fernando J. Pacheco, Angela S. Morabito, Cassio Murilo Hidalgo-Filho, Maria Tallawi, Mira Al Saoub, Nehemias Guevara, Oyepeju Abioye, Rebekah Kaufman, Narjust Florez
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Introduction Young-onset lung cancer, most often defined as diagnosis at or before age 50, is increasingly recognized as a biologically, molecularly, and psychosocially distinct disease rather than an early-arising version of the cancer seen in older adults, yet clinical guidance in thoracic oncology has been built almost entirely from older, smoking-predominant populations. This gap matters because young patients are less likely to have smoked and are disproportionately enriched for targetable oncogenic driver mutations, a difference that reshapes diagnosis, treatment, and survivorship at every step. Methods We present a practical, five-part clinical guide for clinicians managing this population, moving from initial workup through long-term survivorship. The guide is intended for oncologists and multidisciplinary teams and is anchored to US guidelines, with reference to European recommendations. Literature was identified through targeted PubMed/MEDLINE searches, supplemented by current society guidelines, citation tracking, and author expertise, with priority given to phase III trials, society guidelines, population-based and institutional studies of patients aged ≤50 years, and adolescent and young adult-specific psychosocial and survivorship literature. As a narrative clinical guide, this review did not follow systematic review methodology. Results The guide addresses diagnostic delay and the molecular and imaging workup required given the high prevalence of driver mutations and brain metastases; time-sensitive pre-treatment referrals (genetic counseling, fertility preservation, social work, and psychosocial assessment) that must begin in parallel within the first clinical visits without delaying urgent treatment; stage- and mutation-directed therapy, including the growing role of adjuvant targeted therapy in this population; toxicities that are either more frequent in younger patients or carried over a much longer survivorship horizon; and survivorship planning encompassing early palliative care, fertility follow-up, financial toxicity, and return to work. Fertility, psychosocial health, and financial burden recur throughout rather than belonging to any single stage of care. Discussion This review is intended as a point-of-care resource built on a central premise: young adults with lung cancer require clinicians who treat molecular and psychosocial complexity as inseparable parts of the same clinical problem, not as sequential concerns addressed only after cancer-directed treatment ends.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (100)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 80 more references
A free account opens the rest of the citing papers and references on every paper’s page.